HighTower Advisors LLC Acquires Shares of 10,228 Acelyrin, Inc. (NASDAQ:SLRN)

HighTower Advisors LLC acquired a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 10,228 shares of the company’s stock, valued at approximately $50,000.

A number of other institutional investors have also recently bought and sold shares of the business. Verition Fund Management LLC increased its stake in Acelyrin by 55.1% in the third quarter. Verition Fund Management LLC now owns 110,115 shares of the company’s stock valued at $543,000 after acquiring an additional 39,100 shares during the last quarter. Martingale Asset Management L P bought a new position in shares of Acelyrin in the 3rd quarter valued at $485,000. Acuta Capital Partners LLC acquired a new position in shares of Acelyrin in the third quarter valued at approximately $1,795,000. Charles Schwab Investment Management Inc. grew its stake in shares of Acelyrin by 81.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after purchasing an additional 273,604 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Acelyrin in the third quarter valued at about $77,000. Institutional investors own 87.31% of the company’s stock.

Acelyrin Price Performance

NASDAQ SLRN opened at $3.32 on Friday. The business’s fifty day moving average is $4.85 and its 200-day moving average is $4.95. Acelyrin, Inc. has a one year low of $3.06 and a one year high of $8.89. The stock has a market capitalization of $333.08 million, a price-to-earnings ratio of -1.35 and a beta of 1.63.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SLRN shares. HC Wainwright reaffirmed a “neutral” rating and issued a $8.00 price objective on shares of Acelyrin in a research note on Wednesday, December 11th. Wells Fargo & Company dropped their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.